-
Technology
-
Industry
-
Solutions
-
- ASSET MANAGEMENT
- AUGMENTED & VIRTUAL REALITY
- COLLABORATION
- CONVERSATIONAL
- CUSTOMER EXPERIENCE MANAGEMENT
- CUSTOMER RELATIONSHIP MANAGEMENT
- CYBER SECURITY
- DATA CENTER
- DIGITAL CUSTOMER EXPERIENCE
- DOCUMENT MANAGEMENT
- EHS SOFTWARE
- ELECTRONIC DATA INTERCHANGE
- ENTERPRISE DATA MANAGEMENT
- ENTERPRISE DATA QUALITY MONITORING
- ENTERPRISE RESOURCE PLANNING
- ENTERPRISE RISK MANAGEMENT
- ENTERPRISE-GRADE WEB DATA SOLUTIONS
- FACILITY MANAGEMENT
- FIELD SERVICE
- GAMIFICATION
- IDENTITY AND ACCESS MANAGEMENT
- INFRASTRUCTURE
- IT SERVICE MANAGEMENT
- MANAGED IT SERVICES
- PAYMENT AND CARD
- PROJECT MANAGEMENT
- SOFTWARE TESTING
- STORAGE
- VIDEO SOLUTIONS
- WORKFLOW
-
-
Platforms
-
Functions
- Leadership Perspectives
- Innovation Insights
- Research
- Magazines
- News
- CXO Awards

CAMBRIDGE, MA: Agilis Biotherapeutics, a biotechnology company announces a license agreement with the University of South Florida (USF) for the treatment of Angelman Syndrome (AS). Under the terms of the agreement, Agilis will be granted worldwide, exclusive rights to AS gene therapy candidates and related intellectual property.